Creating a database for colorectal cancer in China
Official title: Chinese Colorectal Cancer Database
Run by Beijing Friendship Hospital · NCT05434026 · Data updated 2026-11-12
This study is creating a detailed database of colorectal cancer patients in China to help improve treatment and understanding of the disease in that population.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 200000 (estimated) |
| Sponsor | Beijing Friendship Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | August 3, 2022 |
| Main results expected | June 22, 2032 |
| Study ends | June 22, 2032 |
| Registry record updated | August 3, 2022 |
| Trial ID | NCT05434026 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with adenocarcinoma of the colon who are tolerable to surgery and willing to participate.
✕Probably not a fit
Patients who cannot tolerate surgery or have a history of serious mental illness may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a comprehensive clinical database for colorectal cancer patients in China, capturing essential clinical data such as symptoms, complications, laboratory results, and postoperative outcomes. By focusing on patients undergoing colorectal cancer surgery, the study seeks to reflect the unique characteristics and trends of this disease within the Chinese population. The collected data will support clinical practice and academic research, ultimately guiding future studies and improving patient care in colorectal cancer. Additionally, the study will provide valuable insights and data support to national health authorities.
Why it matters
Potential benefit: If successful, this study could enhance understanding and treatment of colorectal cancer in China, leading to improved patient outcomes.
How similar studies have gone: While similar observational studies have been conducted globally, this specific approach to creating a localized database for colorectal cancer in China is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * adenocarcinoma of the colon by biopsy * tolerable to surgery * be able to understand and willing to participate in this trial with signature Exclusion Criteria: * can not tolerate the surgery * history of serious mental illness * the researchers believe the patients should not enrolled in
Where it's running
-
Zhongtao Zhang
Beijing, China Recruiting
Study contacts
- Study coordinator: Zhongtao Zhang
- Email: zhangzht@ccmu.edu.cn
- Phone: 13801060364
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Single vs. double stapling and purse-string techniques after rectal cancer surgery
This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
Rectal cancer registry to track real-world treatments and outcomes
This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.
-
Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery
This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.
-
Active surveillance vs chemoradiotherapy after local removal of intermediate-risk T1 rectal cancer
This study tests whether close follow-up alone after local removal of early rectal cancer can match the cancer control of adding chemoradiotherapy, while reducing treatment-related side effects.
-
Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer
This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.